ストックスクリーナーアプリを入手
0.7071
11.54%
-0.0922
プレマーケット:
.72
0.0129
+1.82%
前日終値:
$0.7993
開ける：
$0.717
24時間の取引高:
1.41M
Relative Volume:
1.04
時価総額：
$84.82M
収益：
-
当期純損益:
$-225.14M
株価収益率:
-0.3608
EPS:
-1.96
ネットキャッシュフロー:
$-192.27M
1週間 パフォーマンス:
-11.38%
1か月 パフォーマンス:
+3.60%
6か月 パフォーマンス:
-56.08%
1年 パフォーマンス:
-32.01%
1日の値動き範囲:
$0.68
$0.7671
1週間の範囲:
$0.68
$0.81
52週間の値動き範囲:
$0.3546
$2.74
Invivyd Inc Stock (IVVD) Company Profile
IVVD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
0.7071 | 95.89M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-05 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-03-26 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | 開始されました | H.C. Wainwright | Buy |
Invivyd Inc (IVVD) 最新ニュース
Invivyd Q2 2025 slides: Revenue growth amid missed profitability target - Investing.com
Senior Manager/Associate Director, Marketing Waltham/Bostonwill consider remo at Invivyd - Mediabistro
Invivyd Posts Q2 2025 Earnings Miss with Sustained Market Pressure - AInvest
Why Invivyd's Earnings Miss Masks a High-Conviction Long-Term Play in Monoclonal Antibody Innovation - AInvest
Invivyd Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Invivyd Secures FDA Approval for Streamlined Approval Pathway of COVID-19 Monoclonal Antibody VYD2311 - AInvest
Invivyd Stock: Analyst Lowers Price Target to $3.00, Maintains 'Buy' Rating - AInvest
Invivyd Inc Q2 2025 Earnings: Revenue Surges, Earnings Miss Estimates - AInvest
Pediatrix Medical Group, Inc. shares rise 2.77% intraday after Invivyd's FDA alignment for VYD2311 COVID-19 vaccine. - AInvest
Invivyd, Inc. shares fall 11.51% intraday despite FDA alignment on rapid pathway for VYD2311. - AInvest
Alignment Healthcare shares rise 1.89% premarket after Invivyd aligns with FDA on rapid pathway for COVID-19 vaccine alternative. - AInvest
Canopy Growth Corporation shares rise 5.37% premarket after Invivyd's FDA alignment on rapid pathway for COVID-19 vaccine alternative. - AInvest
Invivyd's VYD2311: A High-Conviction Play in Monoclonal Antibody-Based COVID-19 Prevention - AInvest
Invivyd 2025 Q2 Earnings Strong Performance with 69.0% Net Loss Reduction - AInvest
Invivyd earnings missed by $0.10, revenue fell short of estimates - Investing.com Canada
Invivyd Revenue Jumps 413 Percent in Q2 - The Globe and Mail
Invivyd's Path to Profitability: Can VYD2311 and Strategic Pivots Turn the Tide? - AInvest
Invivyd Revenue Jumps 413 Percent in Q2 - The Motley Fool
Invivyd Receives FDA Guidance on Rapid Path to Potential BLA Approval for COVID-19 Antibody - AInvest
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Invivyd aligns with FDA on pathway to approval of COVID-19 vaccine VYD2311 - TipRanks
Invivyd Aligns with FDA for Rapid Approval Pathway - TipRanks
Invivyd Q2 2025: $11.8mln revenue, 413% YoY growth, VYD2311 approval pathway. - AInvest
Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Invivyd, Inc. SEC 10-Q Report - TradingView
Invivyd announces FDA alignment on BLA pathway for COVID-19 antibody - Investing.com
Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19 - The Manila Times
Press Release: Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights - 富途牛牛
FDA Backs New Non-Vaccine COVID Protection: Invivyd's Antibody Treatment Could Replace Vaccines - Stock Titan
Measuring Invivyd Inc.’s beta against major indicesIndex Update & Weekly Breakout Stock Alerts - Newser
Invivyd Inc. stock daily chart insightsVolume Confirmed Setup with Entry Confidence - Newser
Can trapped investors hope for a rebound in Invivyd Inc.Free Weekly Potential Breakout Stock List - Newser
Invivyd Inc. Testing Reversal Zone on Weekly ChartEntry Alert Based on Volume Spikes Detected - beatles.ru
Invivyd Inc. stock outlook for YEARSmart Forecast Signals from AI Models - Newser
Leading vs lagging indicators on Invivyd Inc. performanceConsistent Return Setup with Exit Strategy - Newser
Invivyd Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView
What makes Invivyd Inc. stock price move sharplyExplosive earning power - Jammu Links News
What is the dividend policy of Invivyd Inc. stockRecord-breaking capital gains - Jammu Links News
How volatile is Invivyd Inc. stock compared to the marketGet real-time updates on market trends - Jammu Links News
What drives Invivyd Inc. stock priceMaximize portfolio value with smart investment plans - Jammu Links News
Is Invivyd Inc. stock overvalued or undervaluedAchieve breakthrough gains with expert advice - Jammu Links News
What institutional investors are buying Invivyd Inc. stockMarket-crushing stock picks - Jammu Links News
How strong is Invivyd Inc. company’s balance sheetAchieve remarkable returns with smart investing - Jammu Links News
What are the latest earnings results for Invivyd Inc.Free Stock Index Interpretation - Jammu Links News
What catalysts could drive Invivyd Inc. stock higher in 2025Rapidly growing investment returns - Jammu Links News
What are analysts’ price targets for Invivyd Inc. in the next 12 monthsInvest smarter with expert trading signals - Jammu Links News
How does Invivyd Inc. compare to its industry peersExplosive market performance - Jammu Links News
How does Invivyd Inc. generate profit in a changing economyUnlock powerful trading techniques - Jammu Links News
What analysts say about Invivyd Inc. stockInvest smarter with real-time trading alerts - Jammu Links News
What is the risk reward ratio of investing in Invivyd Inc. stockOutstanding capital growth - Jammu Links News
What are the technical indicators suggesting about Invivyd Inc.Build a winning investment strategy today - jammulinksnews.com
Invivyd Inc (IVVD) 財務データ
収益
当期純利益
現金流量
EPS
Invivyd Inc (IVVD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MCGUIRE TERRANCE | Director |
Dec 27 '24 |
Sale |
0.52 |
83,744 |
43,647 |
3,256,776 |
| MCGUIRE TERRANCE | Director |
Dec 30 '24 |
Sale |
0.48 |
86,545 |
41,784 |
3,170,231 |
| MCGUIRE TERRANCE | Director |
Dec 20 '24 |
Sale |
0.42 |
119,805 |
50,725 |
3,568,274 |
| MCGUIRE TERRANCE | Director |
Dec 26 '24 |
Sale |
0.54 |
83,817 |
45,563 |
3,340,520 |
| MCGUIRE TERRANCE | Director |
Dec 24 '24 |
Sale |
0.51 |
68,161 |
34,503 |
3,424,337 |
| MCGUIRE TERRANCE | Director |
Dec 23 '24 |
Sale |
0.45 |
75,776 |
34,076 |
3,492,498 |
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):